LaunchTrends: Xtandi is a series of three post-launch syndicated reports designed to track physician perception, uptake and the competitive environment of Xtandi in MCRPC
According to all surveyed oncologists, more than half first-line symptomatic MCRPC
patients receive docetaxel, nearly a third receive Zytiga in the second-line and nearly a quarter receive Jevtana in the third-line setting.
With respect to important attributes of therapies used to treat MCRPC
, surveyed physicians (both urologists and oncologists) consider improving overall survival the most significant attribute when choosing an agent to treat MCRPC
, nevertheless, pain palliation is also perceived to be a highly important attribute; conversely, attributes associated with drug sales representatives and patient preference are perceived to be less important.
Janssen recently filed for FDA approval for Zytiga in the asymptomatic/minimally symptomatic,chemotherapy-naove MCRPC setting; interviewed physicians are optimistic about Zytiga in this setting.
Furthermore, more than a third of surveyed physicians select enzalutamide (formerly MDV-3100) as one of the top three emerging therapies that will pose the biggest competitive threat to Zytiga in the treatment of MCRPC.